Literature DB >> 23534568

Tolvaptan in autosomal dominant polycystic kidney disease.

Vicente E Torres, Ron T Gansevoort, Frank S Czerwiec.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23534568     DOI： 10.1056/NEJMc1300762

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Hannah A Blair; Gillian M Keating
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

2.  Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan.

Authors:  Hirayasu Kai; Yuki Shinozaki; Airi Nishikubo; Megumi Watanabe; Takashi Tawara; Mamiko Iwase; Ryouya Tsunoda; Noriaki Moriyama; Toshiaki Usui; Tetsuya Kawamura; Kei Nagai; Masahiro Hagiwara; Chie Saito; Naoki Morito; Joichi Usui; Kunihiro Yamagata
Journal:  CEN Case Rep       Date:  2015-11-17

Review 3.  Physiological insights into novel therapies for nephrogenic diabetes insipidus.

Authors:  Jeff M Sands; Janet D Klein
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-17

Review 4.  The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

5.  Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.

Authors:  Kevin R Kipp; Samantha L Kruger; Margaret F Schimmel; Nikki Parker; Jonathan M Shillingford; Christopher P Leamon; Thomas Weimbs
Journal:  Am J Physiol Renal Physiol       Date:  2018-05-02

6.  Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis.

Authors:  Hervé Husson; Sarah Moreno; Laurie A Smith; Mandy M Smith; Ryan J Russo; Rose Pitstick; Mikhail Sergeev; Steven R Ledbetter; Nikolay O Bukanov; Monica Lane; Kate Zhang; Katy Billot; George Carlson; Jagesh Shah; Laurent Meijer; David R Beier; Oxana Ibraghimov-Beskrovnaya
Journal:  Hum Mol Genet       Date:  2016-04-05       Impact factor: 6.150

7.  Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease.

Authors:  Michelle H T Ta; Kristina G Schwensen; Sheryl Foster; Mayuresh Korgaonkar; Justyna E Ozimek-Kulik; Jacqueline K Phillips; Anthony Peduto; Gopala K Rangan
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

Review 8.  A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics.

Authors:  Giovanna Capolongo; Giovambattista Capasso; Davide Viggiano
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

Review 9.  Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD.

Authors:  Roberto Pagliarini; Christine Podrini
Journal:  Front Med (Lausanne)       Date:  2021-11-24

10.  Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency.

Authors:  Ming-Yang Chang; Tsu-Lin Ma; Cheng-Chieh Hung; Ya-Chung Tian; Yung-Chang Chen; Chih-Wei Yang; Yi-Chuan Cheng
Journal:  Sci Rep       Date:  2017-08-02       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.